Big Platelets in Hyperlipidemic Patients

J. Fuchs, Y. Beigel, P. Green, B. Zlotikamien, E. Davidson, Z. Rotenberg, I. Weinberger*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Both “big” platelets and hyperlipidemia are associated with increased coronary risk. This study was undertaken to search for a possible effect of various hypolipidemic drugs on big platelets. The percentage of big platelets, assessed microscopically, was measured in 66 patients who had hyperlipidemia of various types. Twenty‐seven patients with hypertriglyceridemia were randomly selected to receive either fish oil or placebo in a crossover study. Another group of 39 patients with hypercholesterolemia, among them 13 with heterozygous familial hypercholesterolemia (FH), received lovastatin. The pretreatment level of big platelets was elevated, and similar in all groups: 23.3 ± 12% versus 22 ± 9%, in the fish oil versus placebo group, 19.1 ± 6.3% versus 24 ± 11% in the FH versus non‐FH primary hypercholesterolemia group (reference value, 6.8 ± 3.5%). After treatment, despite the improvement in lipoprotein profile, the percentage of big platelets did not change. The relationship between lipid reduction and big platelets is thus questionable, and necessitates further study. 1992 American College of Clinical Pharmacology

Original languageEnglish
Pages (from-to)639-642
Number of pages4
JournalJournal of Clinical Pharmacology
Issue number7
StatePublished - Jul 1992


Dive into the research topics of 'Big Platelets in Hyperlipidemic Patients'. Together they form a unique fingerprint.

Cite this